Last $14.13 USD
Change Today -0.095 / -0.67%
Volume 5.7K
ALPMY On Other Exchanges
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc-unsp adr (ALPMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/4/14 - $15.77
52 Week Low
04/14/14 - $10.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

astellas pharma inc-unsp adr (ALPMY) Related Businessweek News

View More BusinessWeek News

astellas pharma inc-unsp adr (ALPMY) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., and Dana-Farber Cancer Institute. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc-unsp adr (ALPMY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

astellas pharma inc-unsp adr (ALPMY) Key Developments

Medivation, Inc. and Astellas Pharma, Inc. Announce Presentation of Stage 1 and Preliminary Stage 2 Data from Phase 2 Study

Medivation, Inc. and Astellas Pharma Inc. announced the presentation of Stage 1 and preliminary Stage 2 data from a Phase 2 study evaluating the use of enzalutamide as a single agent for the treatment of advanced androgen receptor positive (AR+), triple negative breast cancer (TNBC). Data was presented at the 37th Annual San Antonio Breast Cancer Symposium. Stage 1 Results from MDV3100-11: A 2-Stage Study of Enzalutamide (ENZA), an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-Negative Breast Cancer (TNBC) (Abstract # P5-19-09). Patients with any amount of AR staining by immunohistochemistry could be enrolled in the study (n=42 in Stage 1, n=118 in total). The primary endpoint was clinical benefit rate, defined as the portion of Evaluable patients (= 10% AR staining in tumor cells and a post-baseline assessment) who had a complete response, partial response, or stable disease for at least 16 weeks. There was no limit to prior therapy. In Stage 1, 26 of the 42 enrolled women comprised the Evaluable population. In the 26 Evaluable women, the primary endpoint was achieved in 42% (11 of 26) including 1 partial response in a patient with measurable disease and 1 complete response in a patient with non measurable disease. Clinical benefit rate = 24 weeks was achieved in 35% (9 of 26). The clinical benefit rate > 16 weeks in Stage 1 was sufficiently high to enable both the expansion into Stage 2 and early rejection of the null hypothesis. While data are not yet mature (anticipated 2015), 1 additional complete response and 3 additional partial responses have been observed to date in the additional 76 patients enrolled following Stage 1, for a total of 6 complete or partial responses in both Stages as of November 10, 2014.

Astellas Pharma Inc. Announces End of License Agreement with Janssen Biotech, Inc. to Develop and Commercialize ASP015K

Astellas Pharma Inc. announced that its license agreement with Janssen Biotech, Inc. to develop and commercialize ASP015K, Astellas' oral Janus Kinase (JAK) inhibitor, will end effective January 15, 2015. Janssen has exercised its right to terminate the license agreement, which was signed in 2012. Upon the effective date of termination, Astellas will regain all rights granted to Janssen. Astellas is now considering the future plan for ASP015K outside Japan, but will continue the Phase 3 development program which was initiated in Japan. Upon the termination of the license agreement, Astellas will not revise its financial forecast for the current fiscal year (from April 1, 2014 to March 31, 2015).

Astellas Pharma, Inc. Presents at Nomura Investment Forum 2014, Dec-02-2014

Astellas Pharma, Inc. Presents at Nomura Investment Forum 2014, Dec-02-2014 . Venue: The Palace Hotel Tokyo, Tokyo, Japan.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $14.13 USD -0.095

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $139.90 USD +1.44
CSL Ltd A$87.47 AUD -0.19
Mylan Inc/PA $56.97 USD +0.39
Takeda Pharmaceutical Co Ltd ¥5,057 JPY -7.00
Valeant Pharmaceuticals International Inc C$163.19 CAD -0.41
View Industry Companies

Industry Analysis


Industry Average

Valuation ALPMY Industry Range
Price/Earnings 30.9x
Price/Sales 2.9x
Price/Book 2.7x
Price/Cash Flow 21.2x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at